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Hypertension is the leading single risk factor for cardiovascular disease, stroke and death 
worldwide. Accurate measurement of blood pressure (BP) is one of the most important of all 
medical tests, yet there is global marketing and sale of BP measurement devices (BPMDs) for 
home or clinical use that have not undergone rigorous accuracy (validation) testing. A key factor 
underlying this problem is that many regulatory authorities do not require manufacturers to 
conduct validation testing according to standardized international protocols. This means that 
manufacturers can obtain approval for the sale of BPMDs even though they have only conducted 
‘in house’ testing, using variable and undisclosed methods to assess and report the accuracy of 
BPMDs. There is also no requirement that results of the internal company testing be made 
publicly available. Many other validation study ‘loopholes’ exist that altogether create a clear 
commercial conflict of interest that raises meaningful concerns over the quality of BPMD 
validation results that are provided to regulatory authorities.1 
It is perhaps not surprising then, that some BPMDs cleared for sale by regulatory 
authorities do not pass accuracy testing when assessed by parties independent from the 
manufacturer using rigorous standardized international protocols. In one study that evaluated 
accuracy among 74 automated BPMDs used by people in the community for home BP 
monitoring, only 15% of non-validated BPMDs were found to be within 4 mmHg of 
simultaneously measured mercury auscultation compared with 68% among the more rigorously 
validated BPMDs.2 It is hard to predict whether a BPMD will over- or under-estimate BP as 
compared with mercury auscultation as the measurement standard, and a systolic BP error 
magnitude greater than 10 mmHg is not uncommon. This is a serious clinical concern potentially 
contributing to inappropriate medical care, either through unnecessarily prescribed medication in 
response to falsely high BP results or failure to recognize and treat high BP in the setting of 
falsely low BP results. Widespread commercial availability of non-validated BPMDs with 
inherent inaccuracy of measurements could undermine efforts to reduce the global burden from 
cardiovascular disease.1 
Hypertension guidelines and professional associations worldwide have repeatedly 
emphasized that home BP monitoring must only be undertaken using BPMDs that have passed 
accepted national or international validation protocols.3 Recommendations to exclude 
manufacturer personnel from involvement in analysis or publication of validation studies have 
also been made. Yet, this above advice has failed to prompt remediating action, and we now 
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have a situation whereby more than 3300 BPMDs worldwide are currently marketed (by 450+ 
companies), but less than 15% of these BPMDs have undergone independent validation testing. 
A recent market scan of BPMDs available for online purchase in Australia showed that only 
18.3% of upper arm cuff BPMDs had passed international validation protocols. More 
concerningly, only 5.5% of all BPMDs sold by major international e-commerce enterprises were 
rigorously validated. This study also identified a large and emerging online presence of cuff-less 
wrist-band BP devices for sale, none of which is validated.4 The extent to which patients may be 
using these wrist-band type BPMDs are not known, but represents yet another potential adverse 
influence on best-practice care related to hypertension. Unaware of the problems, even consumer 
advocacy agencies recommend purchase of non-validated BP devices.  
Oscillometric BPMDs generally estimate mean arterial pressure and employ a propriety 
algorithm to estimate systolic and diastolic BP that may or may not be extrapolatable to diverse 
populations with different ages, body mass index, and various co-morbidities. Several BP-related 
organizations have made repeated calls for action related to these issues, including better 
identification of appropriately validated BPMDs. This has led to the development of several 
region-specific validated device listings that people can access online, including the U.S.-based 
BPMDs endorsed by the American Medical Association (Table 1). Clinicians and patients can 
search for validation information on BPMDs on the weblinks relevant to their geographic region. 
Attention should be paid not only to the specific BPMD manufacturer but also to the specific 
device model, as each model from a single company may not achieve the same ratings. Users 
will note variability in the quality of search engines, as well as some discrepancy in 
recommendations provided between different listings, which can create confusion. This is due to 
subtle variations in the criteria used among organizations to denote acceptable validation, and 
emphasizes the need for one universally accredited list of BPMDs, a recommendation of the 
Lancet Commission on Hypertension Group.1 This group has also developed a practical guide for 
consumers to identify BPMD validation credentials (Table 1). 
Moving forward, we believe that independent validation testing should be conducted for 
all marketed BPMDs.1 Rigorous validation process should be performed according to the 
International Organization for Standardization (ISO) 81060-2:2018 protocol5, which was 
developed by experts from the US Association for Advancement of Medical Instrumentation, as 
well as the European Society of Hypertension. The proof of compliance should be made publicly 
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available, preferably by publication in the peer-reviewed literature. The ISO protocol has major 
similarities to most previous protocols, which all fulfil the mutual aim of establishing the 
minimum accuracy standards for BPMDs.5 The ISO protocol requires a minimum sample size of 
85 participants and a minimum of 255 valid pairs of measurements recorded simultaneously by 
two observers who have been trained in proper methodology using a double stethoscope 
(deflation rate 2 – 3 mmHg/s). Our recommendation for independent validation testing before 
BPMDs are marketed and sold is relevant to all consumers of BP devices, from individuals 
seeking to self-measure BP at home,3 to retailers, health care providers, government and non-
government organizations alike. We invite all interested stakeholders to support us in this call to 
action and advocate for the marketing and sale of BPMDs restricted to those that have been 
independently validated as a fundamental prerequisite to improving global BP control. Efforts 
are also needed to disseminate this information to healthcare providers and general public to 
promote an uptake in the use of validated BPMDs.  
5 
 
Conflict of interest disclosures 
Dr Sharman’s university has received equipment and research funding from manufacturers of BP 
devices but he has no personal commercial interests related to BP companies. 
Dr Padwal is the Canadian representative to the ISO Sphygmomanometer committee and sits on 
the AAMI Sphygmomanometer committee. He is co-founder of a digital health company (mmHg 
Inc.), based at the University of Alberta creating software innovations in BP measurement. 
Dr Campbell was a paid consultant to the Novartis Foundation (2016–2017) to support their 
programme to improve hypertension control in low-to-middle income countries which includes 
travel support for site visits and a contract to develop a survey. He has provided paid consultative 
advice on accurate BP assessment to Midway Corporation (2017) and is an unpaid member of 
World Action on Salt and Health (WASH). 
 
Acknowledgements 
The following people provided support to the authors as part of collaborations to improve the 
global availability of accurate cuff blood pressure measurement devices: Michael Hecht-Olsen, 
Aletta E. Schutte, Christian Delles, Vivekanand Jha, Reinhold Kreutz, Andrew E. Moran, 
Marcelo Orias, C Venkata S Ram, Robert A. Harrington, Karen Sliwa and Xin-Hua Zhang. 
References 
1. Sharman JE, O’Brien E, Alpert B, et al. Lancet Commission on Hypertension Group 
Position Statement on the Global Improvement of Accuracy Standards for Devices That Measure 
Blood Pressure. Journal of Hypertension. 2020;38:21-29. 
2. Akpolat T, Dilek M, Aydogdu T, et al. Home Sphygmomanometers: Validation Versus 
Accuracy. Blood Pressure Monitoring. 2009;14:26-31. 
3. Shimbo D, Artinian NT, Basile JN, et al. Self-Measured Blood Pressure Monitoring at 
Home: A Joint Policy Statement from the American Heart Association and American Medical 
Association. Circulation. 2020;141 Epub Ahead of Print. 
4. Picone DS, Deshpande R, Schultz MG, et al. Non-Validated Home Blood Pressure 
Devices Dominate the Online Marketplace in Australia: Major Implications for Cardiovascular 
Risk Management. Hypertension. 2020;75:1593-1599. 
5. Stergiou GS, Alpert B, Mieke S, et al. A Universal Standard for the Validation of Blood 
Pressure Measuring Devices: Association for the Advancement of Medical 
Instrumentation/European Society of Hypertension/International Organization for 
Standardization (Aami/Esh/Iso) Collaboration Statement. Hypertension. 2018;71:368-374. 
  
Formatted: Font color: Red
6 
 
Table 1. Weblinks to listings of blood pressure devices that have been independently assessed 
for accuracy according to scientific validation protocols 
Society, organisation or company Weblink 
American Medical Association www.validatebp.org  
British and Irish Hypertension Society https://bihsoc.org/bp-monitors/ 
dabl Educational Trust  
(no longer actively updated) 
http://www.dableducational.org/  







Japanese Society of Hypertension 
(in Japanese) 
http://www.jpnsh.jp/com_ac_wg1.html   
Medaval (for profit) https://medaval.ie/  
STRIDE BP (European based) https://stridebp.org/  
A consumer guide to using these resources can be found at: 
https://www.menzies.utas.edu.au/documents/pdfs/Blood-pressure-devices.pdf  
Note: For profit companies may be subject to conflict of interest. 
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